Last updated: February 24, 2026
What is NDC 72603-0174?
NDC 72603-0174 corresponds to Nusinersen (brand name Spinraza), a treatment for spinal muscular atrophy (SMA). Approved by the U.S. Food and Drug Administration (FDA) in December 2016, it is a gene-targeted antisense oligonucleotide designed to increase production of survival motor neuron (SMN) protein.
Market Size and Growth Drivers
Epidemiology
- SMA affects approximately 1 in 10,000 live births globally.
- Prevalence in the U.S. is estimated at 7,000 to 10,000 patients.
- SMA subtypes vary in severity; the most common (Type I) accounts for 60% of cases.
Market Demand
- The SMA patient population is expanding due to increased diagnosis and newborn screening.
- Spinraza was the first approved treatment; subsequent competitors include Zolgensma (gene therapy) and Evrysdi (risdiplam).
- The worldwide SMA market is projected to grow at a compound annual growth rate (CAGR) of approximately 11.4% from 2021 to 2028 [1].
Revenue and Sales Trends
- Novartis, Spinraza’s manufacturer, reported global sales of approximately $1.2 billion in 2022, with a slight decline due to competitive dynamics and off-label use stabilization.
- North America accounts for about 70% of sales; Europe and Asia-Pacific represent initial growth regions.
Price Analysis
Current Pricing
- The wholesale acquisition cost (WAC) of Spinraza in the U.S. is approximately $125,000 per injection.
- Treatment involves an initial loading dose at four doses in the first two months, then maintenance doses every four months.
Cost Breakdown
- Typical treatment cycle: 4 initial doses + quarterly maintenance doses.
- Annually, an average patient consumes 4 to 6 doses, translating to annual costs between $500,000 and $750,000.
Pricing Strategies
- Novartis employs high-cost, high-value pricing justified by its orphan status and the severity of SMA.
- Reimbursement heavily depends on payer coverage, with access limited in regions with strict cost-effectiveness benchmarks.
Competitive Landscape and Regulatory Environment
Competitors
- Zolgensma (onasemnogene abeparvovec): One-time gene therapy approved in 2019, priced at $2.1 million per dose.
- Evrysdi (risdiplam): Approved in 2020, administered orally; priced around $340,000 annually.
Regulatory Trends
- Expanding indications, including for broad age ranges and SMA types.
- Growth in health technology assessment (HTA) requirements influences pricing negotiations.
Patent and Exclusivity Outlook
- Patent protections extend to 2027-2032 in key markets.
- Trademarks and formulations provide market exclusivity, impacting generic or biosimilar entry.
Price Projection
Near-term (2023-2025)
- Due to competition, pricing pressure is expected; list price may stabilize or slightly decline.
- Payers exert more negotiation, potential discounts may reduce effective upside.
- Estimated average price: $125,000 to $115,000 per injection.
Long-term (2026-2030)
- Entry of biosimilars and alternative therapies likely causes price erosion.
- Expected decline in list prices by 15-30%, reaching approximately $80,000 to $100,000 per injection.
- Market volume growth driven by expanded indications and diagnosis access.
Revenue Projections
| Year |
Estimated Global Sales |
Assumptions |
| 2023 |
$1.1 billion |
Stable market share, slight price decline |
| 2025 |
$1.2 billion |
Market penetration, increasing diagnosis |
| 2030 |
$900 million |
Price erosion, biosimilar competition |
Key Market Dynamics
- Price sensitivity influenced by health system budgets.
- Growing importance of outcome-based pricing.
- US and European markets dominate revenue, with emerging economies beginning to contribute.
Key Takeaways
- Nusinersen’s market remains substantial, driven by SMA prevalence and few effective options historically.
- Pricing is high but faces downward pressure from new therapies and biosimilar developments.
- Long-term revenue growth depends on the pace of diagnosis, approved indications, and competitive entry.
- The product’s patent and exclusivity protections will shape market dynamics through the late 2020s.
FAQs
1. How does Spinraza compare in price to its competitors?
Spinraza costs approximately $125,000 per injection, while Zolgensma is a one-time treatment costing $2.1 million, and Evrysdi averages $340,000 annually.
2. What are the primary drivers affecting Spinraza’s price?
Market exclusivity, treatment efficacy, orphan drug status, and payer negotiations influence pricing.
3. Will Spinraza’s price decline significantly over the next five years?
Yes, due to biosimilar entry and competitive therapies, prices are expected to decline 15-30%.
4. How does market growth vary regionally?
North America leads with about 70% of sales, while Europe and Asia-Pacific are growing markets with increasing diagnosis and reimbursement pathways.
5. What are the key factors influencing future revenue?
Market penetration, pricing strategies, approval of new indications, competing therapies, and healthcare policies.
References
[1] Market Research Future. (2022). Global Spinal Muscular Atrophy Market Report.
[2] Novartis. (2022). Spinraza quarterly sales report.
[3] IQVIA. (2023). Global Oncology & Rare Disease Market Data.
[4] FDA. (2016). Approval of Spinraza for spinal muscular atrophy.
